Navigation Links
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
Date:8/7/2014

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of John A. Bencich as Vice President and Chief Financial Officer (CFO).  John Bencich, an experienced life sciences and technology industry executive, is joining the company effective August 11th, 2014. John will lead the company's financial and administrative operations, reporting directly to OncoGenex President and CEO Scott Cormack.

"John brings to our management team proven financial leadership and strategic corporate growth expertise that will be invaluable as we shape the future of OncoGenex," said Scott Cormack, President and CEO of OncoGenex. "The Board of Directors joins me in welcoming John to his new position and we look forward to his substantial contributions to drive OncoGenex' future success."

"The team at OncoGenex is genuinely committed to making a difference in the lives of people suffering from devastating illnesses. I am honored to join in this mission at this exciting time of execution and growth," commented John Bencich.

Prior to his recent appointment at OncoGenex, John served as CFO of Integrated Diagnostics Inc. overseeing finance, corporate development, accounting and human resource functions. Before joining Integrated Diagnostics in 2012, John was CFO of Allozyne, a private, VC-backed company where he led the company's finance, accounting and information technology groups. Earlier he served as the vice president, CFO and treasurer of Trubion Pharmaceuticals, a publicly traded biotechnology company where he helped complete the successful sale of the company to Emergent BioSolutions. Prior to his role at Trubion, he was the director of finance and corporate controller for Onyx Software Corporation, a publicly traded software company. John started his career at Ernst & Young LLP. He graduated from the University of San Diego with a BA in Accounting, earned his MBA from Seattle University and is a Certified Public Accountant.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account: https://twitter.com/OncoGenex_IR.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
2. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
4. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
5. RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
6. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
7. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
8. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
9. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
10. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
11. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
Breaking Biology News(10 mins):